All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Satellite Symposium | Sequencing of therapy for a patient with TP53-mutated MCL
Bookmark this article
The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to discuss the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia. Professor Steven Le Gouill, CHU de Nantes, Nantes, FR, discusses sequencing of therapy for patients with TP53-mutated mantle cell lymphoma (MCL).
Lymphoma Hub Satellite Symposium: Watch here!
Welcome to the Lymphoma Hub Satellite Symposium.
Please take a moment to complete the survey and answer the following questions to help us gauge your current understanding of the sequencing of therapy for patients with TP53-mutated MCL.
Le Gouill begins by presenting a patient case and discussing the significance of prognostic markers, especially for relapsed cases. The presentation outlines prognostic data around relevant MCL patient characteristics, including the MANTLE-FIRST trial. Le Gouill goes on to review currently available treatment options, as well as introducing novel agents in MCL. Finally, he discusses the encouraging results of the AIM and OAsIs trials, which combine ibrutinib and venetoclax, and ibrutinib, venetoclax, and obinutuzumab, respectively.
Satellite Symposium | Sequencing of therapy for a patient with TP53-mutated MCL
If you would like to download the slides from Steven Le Gouill's presentation, click below.
Download here
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
42 votes - 79 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox